Just my understanding and far from a medical expert
The recent IP of CD19 is a FDA approved drug, a powerful Tcell that can kill tumour cells. But the downside was not only targeting the tumour cells but also the other healthy cells. So it was only approved for the liquid cancers (blood)
CD19 needs a delivery vehicle/agent to selectively target the cancer cells only and that is what CF33 does. It was designed for targeting all types of solid tumours.
CHM has only one product which the CLTX specifically targeting GBM. I don't know why it would be ever linked to an approved Tcell drug CD19 or has any conflict of interest.
IMU is not a Tcell company. It only used an approved Tcell drug to optimise their OV therapy. So CF33 is the key to get succeed.
Imagine if CF33-CD19 does work in the future which potentially a cancer cure for all types of cancers including GBM.
More excited about IMU in the near term.
IMU Price at posting:
31.0¢ Sentiment: Buy Disclosure: Held
(20min delay)